Patents by Inventor Joseph LEVEQUE

Joseph LEVEQUE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES
    Publication number: 20260115295
    Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.
    Type: Application
    Filed: August 20, 2025
    Publication date: April 30, 2026
    Applicant: Synthorx, Inc.
    Inventors: Giovanni ABBADESSA, Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Timothy R. WAGENAAR
  • HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB
    Publication number: 20240245792
    Abstract: Disclosed herein are methods for treating head and neck squamous cell carcinoma (HNSCC) in a subject in need thereof, comprising administering IL-2 conjugates in combination with one or more additional agents.
    Type: Application
    Filed: November 30, 2023
    Publication date: July 25, 2024
    Inventors: Giovanni Abbadessa, Carolina E. Caffaro, Brigitte Demers, Joseph Leveque, Wan-Ju Meng, Marcos Milla, Jerod Ptacin
  • HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB
    Publication number: 20240226309
    Abstract: Disclosed herein are methods for treating head and neck squamous cell carcinoma (HNSCC) in a subject in need thereof, comprising administering IL-2 conjugates in combination with cetuximab.
    Type: Application
    Filed: November 30, 2023
    Publication date: July 11, 2024
    Applicant: Synthorx, Inc.
    Inventors: Giovanni ABBADESSA, Carolina E. CAFFARO, Brigitte DEMERS, Joseph LEVEQUE, Wan-Ju MENG, Marcos MILLA, Jerod PTACIN
  • IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES
    Publication number: 20230416327
    Abstract: Disclosed herein are methods and uses relating to administering IL-2 conjugates or methods useful for the treatment of one or more indications, such as the treatment of proliferative diseases. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-2 conjugates.
    Type: Application
    Filed: April 6, 2023
    Publication date: December 28, 2023
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Laura SHAWVER
  • LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20230381335
    Abstract: Disclosed herein are methods for treating a lung cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with the anti-PD-1 antibody or antigen-binding fragment thereof (e.g., pembrolizumab).
    Type: Application
    Filed: August 10, 2023
    Publication date: November 30, 2023
    Inventors: Giovanni Abbadessa, Carolina E. Caffaro, Brigitte Demers, Joseph Leveque, Wan-Ju Meng, Jerod Ptacin
  • IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB
    Publication number: 20230277627
    Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with pembrolizumab.
    Type: Application
    Filed: April 6, 2023
    Publication date: September 7, 2023
    Applicant: Synthorx, Inc.
    Inventors: Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Laura SHAWVER
  • IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES
    Publication number: 20220016252
    Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 20, 2022
    Applicant: Synthorx, Inc.
    Inventors: Giovanni ABBADESSA, Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Timothy R. WAGENAAR